Literature DB >> 8104217

Accessory molecules involved in antigen-mediated cytolysis and lymphokine production by cytotoxic T lymphocyte subsets. I. Identification of functions for the T cell surface molecules Ly-6C and Thy-1.

R Johnson1, D W Lancki, F W Fitch.   

Abstract

The murine T cell surface molecules Ly-6C and Thy-1 are genetically and structurally distinct, yet they share two interesting properties: both are attached to the plasma membrane through a glycophosphatidylinositol linkage, and some mAb reactive with these molecules can activate T cells. Although mAb for Ly-6C and Thy-1 appear to mimic the function of physiologic ligands, direct evidence for the existence of these putative ligands has not been presented. In this report, we describe CTL clones that use Ly-6C and Thy-1 as accessory molecules for activation of cytolysis and the production of IFN-gamma based on inhibition of these functions with mAb. These studies were facilitated by the derivation of a nonactivating hamster IgM mAb specific for Ly-6C. CTL clones that use Ly-6C and Thy-1 as accessory molecules include a subpopulation of the previously described CD8+ alloreactive CTL that are not inhibited by mAb reactive with CD8, a CD8+ TCR-alpha/beta+ T cell clone specific for HSV glycoprotein D, and a CD4-CD8- TCR-gamma/delta+ T cell clone specific for HSV glycoprotein I. The role of Ly-6C and Thy-1 in target cell recognition is to some degree tissue-specific with respect to the APC/target cell. A mAb specific for Ly-6C appears to inhibit activation by prevention of adhesion between the effector cells and the target cells. This is the most direct evidence to date of a functional ligand for Ly-6C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104217

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms.

Authors:  Krupakar Jayarapu; Micah Kerr; Susan Ofner; Raymond M Johnson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

2.  Ly-6C regulates endothelial adhesion and homing of CD8(+) T cells by activating integrin-dependent adhesion pathways.

Authors:  A Hänninen; I Jaakkola; M Salmi; O Simell; S Jalkanen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

3.  Involvement of Ly6C, 4-1BB, and KLRG1 in the activation of lamina propria lymphocytes in the small intestine of sanroque mice.

Authors:  Dina Montufar-Solis; Alexander Williams; Nadarajah Vigneswaran; John R Klein
Journal:  Biochem Biophys Res Commun       Date:  2016-12-21       Impact factor: 3.575

4.  Inhibition of the function of the FcgammaRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen.

Authors:  L Ding; E M Shevach
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

Review 5.  T-cell activation in the curious world of the intestinal intraepithelial lymphocyte.

Authors:  John R Klein
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Overexpressed Ly-6A.2 mediates cell-cell adhesion by binding a ligand expressed on lymphoid cells.

Authors:  A Bamezai; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

7.  Activation and Costimulation of Intestinal T Cells: Independent and Collaborative Involvement of CD43, OX40, and Ly-6C.

Authors:  Dina Montufar-Solis; John R Klein
Journal:  Curr Immunol Rev       Date:  2005-01

Review 8.  Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

9.  The molecular signature of CD8+ T cells undergoing deletional tolerance.

Authors:  Ian A Parish; Sudha Rao; Gordon K Smyth; Torsten Juelich; Gareth S Denyer; Gayle M Davey; Andreas Strasser; William R Heath
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.